EuropeanJournalofHeartFailure(2014)
doi:10.1002/ejhf.151
Effects of person-centred and integrated
chronic heart failure and palliative home care.
PREFER: a randomized controlled study
Margareta BrÃ¤nnstrÃ¶m1* and Kurt Boman2
1StrategicResearchPrograminHealthCareSciences(SFO-V),â€˜BridgingResearchandPracticeforBetterHealthâ€™,DepartmentofNursing,UmeÃ¥University,UmeÃ¥,Sweden;and
2Researchunit,DepartmentofMedicine,SkellefteÃ¥,InstitutionofPublicHealthandClinicalMedicine,UmeÃ¥University,UmeÃ¥,Sweden
Received4March2014;revised27June2014;accepted11July2014
Aims Weevaluatedtheoutcomeofperson-centredandintegratedPalliativeadvancedhomecaREandheartFailurEcaRe
(PREFER)withregardtopatientsymptoms,health-relatedqualityoflife(HQRL),andhospitalizationscomparedwith
usualcare.
.....................................................................................................................................................................
Methods From January 2011 to October 2012, 36 (26 males, 10 females, mean age 81.9years) patients with chronic heart
andresults failure (NYHA class IIIâ€“IV) were randomized to PREFER and 36 (25 males, 11 females, mean age 76.6years)
to the control group at a single centre. Prospective assessments were made at 1, 3, and 6 months using the
EdmontonSymptomAssessmentScale,EuroQol,KansasCityCardiomyopathyQuestionnaire,andrehospitalizations.
Between-group analysis revealed that patients receiving PREFER had improved HRQL compared with controls
(57.6Â±19.2vs.48.5Â±24.4,age-adjustedP-value=0.05).Within-groupanalysisrevealeda26%improvementinthe
PREFERgroupforHRQL(P=0.046)comparedwith3%(P=0.82)inthecontrolgroup.Nauseawasimprovedinthe
PREFERgroup(2.4Â±2.7vs.1.7Â±1.7,P=0.02),andtotalsymptomburden,self-efficacy,andqualityoflifeimproved
by18%(P=0.035),17%(P=0.041),and24%(P=0.047),respectively.NYHAclassimprovedin11ofthe28(39%)
PREFERpatientscomparedwith3ofthe29(10%)controlpatients(P=0.015).Fifteenrehospitalizations(103days)
occurredinthePREFERgroup,comparedwith53(305days)inthecontrolgroup.
.....................................................................................................................................................................
Conclusion Person-centred care combined with active heart failure and palliative care at home has the potential to improve
qualityoflifeandmorbiditysubstantiallyinpatientswithseverechronicheartfailure.
..................T.r.ia.l..re.g.i.s.t.ra.t.i.o.n.:.N.C..T.0.1.3.0.4.3.8.1.............................................................
Keywords Heartfailure â€¢ Integratedcare â€¢ Palliativecare â€¢ Person-centredcare â€¢ RCT
Introduction
Chronicheartfailure(CHF)isaseriousconditionwithaprognosis
worsethanmanyformsofcancer.1 PatientswithCHFhavesymp-
tomsassevereanddistressingasthoseofcancerpatients,butthey
donothaveequalaccesstopalliativecare.2 ThecourseofCHFis
unpredictable,makingitdifficulttoidentifyaspecifictimepointto
introduce palliative care to heart failure management.3 Recently,
wefoundlargedifferencesinthequalityofend-of-lifecareinthe
*Corresponding author. Department of Nursing, UmeÃ¥ University, Campus SkellefteÃ¥, 93187 SkellefteÃ¥, Sweden. Tel: +46 910787241, Fax: +49 91210016, Email:
margareta.brannstrom@nurs.umu.se
..........................
Swedish Register of Palliative Care between patients with heart
disease and those with cancer.4 For example, patients with heart
disease experience more shortness of breath and have fewer
drugs prescribed on demand against the usual symptoms, com-
pared with patients with cancer.4 In addition, patients with CHF
oftenrequirefrequenthospitalizationsandreadmissions,suggest-
ing insufficient management of these patients, which may be due
to the frequency of concomitant chronic diseases. The European
Society of Cardiology (ESC) has pointed out that selected
Â©2014TheAuthors
EuropeanJournalofHeartFailureÂ©2014EuropeanSocietyofCardiology
2 M.BrÃ¤nnstrÃ¶mandK.Boman
Palliative caRE Heart FailurE Clinic CaRe
Integrated palliative and heart failure care
Key components:
Specialized care Person centred
Team based care Structered
Total care Easy access
Key individual Support to close relatives
Support to team members
RELIEF
Physical and Psychological symptoms Social and Existential problems
Figure1 PREFER.Amodelforperson-centredandintegratedcareofpatientswithheartfailure.9
patients require palliative care services in addition to the heart
failuremanagementprogramme.3Guidelines5haveconcludedthat
a great need exists for new models of integrated care, such as
active heart failure and palliative care, in order to facilitate care
equality for dying patients regardless of diagnosis. This idea is
also in line with the World Health Organizationâ€™s description
of palliative care.6 We found some information in the literature
concerning the advantages and effects of an in-hospital specialist
heart failure- and home-based palliative care for patients with
severeCHF.7ACochranereviewshowedthathomepalliativecare
reduces symptom burden, particularly for patients with cancer,
but more research is needed on valid outcomes in populations
with non-malignant conditions and powered studies are required
tocomparedifferentmodelsofhomepalliativecare.8
Here, we report the clinical outcome of a new model that
integrates Palliative advanced home caRE and heart FailurE caRe
(PREFER) for patients with severe CHF (Figure 1) as described
previously.9 Our hypothesis was that the combination of key
components for delivering heart failure care and palliative care
contained in PREFER should reduce the total symptom burden,
increasehealth-relatedqualityoflife(HRQL)andfunctionalcapac-
ity,andreducemorbidity.
OurprimaryaimwastoevaluatetheeffectsofthePREFERinter-
vention on symptom burden, quality of life (QoL), and functional
classescomparedwithusualcare.Thesecondaryaimwastostudy
theeffectofthePREFERmodelonthenumberofhospitalizations
anddaysspentinhospital.
...................................................................................
Methods
Study design and setting
Thiswasaprospectiverandomizedstudywithanopennon-blinded
design.Patientswererandomizedwithenvelopesinblocksof20to
thePREFERinterventiongroup(n=36)ortousualcare(n=36).
Usualcarewasprovidedmainlybygeneralpractitionersordoctors
and/orthenurse-ledheartfailureclinicattheMedicine-Geriatrics
department.After6months(Â±2weeks)thepatientsweretrans-
ferred to the original care provider following the establishment
ofanindividualcareplan.Theresearchcontextwasanadvanced
homecareunitprovidingservicesMondayâ€“Fridayduringtheday
and based in a county hospital located in northern Sweden. The
home visits and the phone calls varied substantially from several
times per day to every other week. Diuretic administration also
variedsubstantiallybetweenpatientsduetotheseverityofheart
failure,fromnonetoseveraltimesperday.Diureticswereadmin-
istered s.c. or i.v. at home on demand for worsening symptoms
whenoraltherapywasinsufficient.Bloodsampling,e.g.fordeter-
minationofelectrolytes,creatinine,andBNP,andtransmissionof
the ECG to the hospital, were performed in the patientâ€™s home.
Noi.v.inotropewasadministeredathome.
Participants
The Department of Medicine-Geriatrics serves a catchment area
of 75 000 inhabitants. The participants in the PREFER trial were
Â©2014TheAuthors
EuropeanJournalofHeartFailureÂ©2014EuropeanSocietyofCardiology
PREFER:arandomizedcontrolledstudy 3
SkellefteÃ¥ hospital catchment area
75 000 inhabitants.
Estimated number of patients with CHF (2%)
~1500 patients.
Estimated NYHA III o IV ~ (32%)
480 patients
Eligible number of patients screened
517
Not fullfilling inclusion
criteria = 213
Contraindications = 202
- distance = 85
Refused participation = 30 - demens = 51
- other severe disease = 30
- other reasons = 36
Randomized
PREFER = 36 CONTROL = 36
Figure2 Flowdiagramofthestudy.CHF,chronicheartfailure.
inhabitantswhohadtheirprimaryhealthcarecentrewithin30km
ofthehospital.
Patients with a confirmed diagnosis of CHF1 and cared for
at the Department of Medicine-Geriatrics or primary healthcare
centres and who met the criteria of the ESC5 were asked to
participate in the study. Inclusion criteria comprised CHF with
NYHA functional classes IIIâˆ’IV symptoms and at least one of
thefollowing:atleastonehospitalizedepisodeofworseningheart
failure that resolved with the injection/infusion of diuretics or
the addition of other heart failure treatment in the preceding 6
monthsandregardedasbeingâ€˜optimallytreatedâ€™accordingtothe
responsiblephysician;needforfrequentorcontinuali.v.support;
chronically poor QoL based on a visual analogue scale (VAS)
score <50; signs of cardiac cachexia, defined as an involuntary
non-oedematousweightlossâ‰¥6%oftotalbodyweightwithinthe
preceding6â€“12months;andlifeexpectancyof<1year.Exclusion
criteria were patients who did not want to participate in the
study;hadseverecommunicationproblems;hadseveredementia
orotherseriousdiseasesinwhichheartfailurewasofsecondary
importance; with other life-threatening illnesses as their primary
diagnosisandanexpectedshortsurvivaltime;whoseprimarycare
centre responsible for their care was located >30km from the
hospital;andwhowerealreadyparticipatinginanotherclinicaltrial.
WeestimatedaprevalenceofCHFof2%(1500),andâˆ¼32%(480)
of these would be in NYHA class IIIâ€“IV according to a Swedish
.............................................................................. registry study.10 We identified 517 patients eligible for the study,
ofwhom72werefinallyrandomized(Figure2).
Randomization and intervention
Patients (n=72) were randomized into either the PREFER inter-
vention(n=36)orthecontrolgroup(n=36).Patientsintheinter-
ventiongroupwereofferedamultidisciplinaryapproachinvolving
collaborationbetweenspecialistsinpalliativeandheartfailurecare,
i.e. specialized nurses, palliative care nurses, cardiologist, pallia-
tivecarephysician,physiotherapist,andoccupationaltherapist.The
patientswerealsoofferedstructured,person-centredcare(PCC)
athome.11 PCCisoneofthekeycomponentsandcornerstones
inthePREFERmodel.PCCisdescribedasapartnershipbetween
patients/carersandprofessionalcaregivers,andincludesinitiating,
workingon,anddocumentingthepartnership.Thestartingpoint
is the patientâ€™s narrative, which is recorded in a structured man-
nerandfromwhichamutualcareplaniscreatedthatincorporates
goalsandstrategiesforimplementationandfollow-up.11
Theinterventionwascarriedoutasfollows:(i)afteridentifying
apatientwhofulfilledtheinclusioncriteriaandhadnoexclusion
criteriaearlierdescribedinthedesignpaper,12aresponsiblephysi-
cianandnursewereidentifiedforeachpatient;(ii)thepatientwas
thencalledforathoroughmedicalexaminationbytheresponsible
physician with identification of co-morbidities and assessment of
physiological, social, and spiritual needs; followed by (iii) meeting
Â©2014TheAuthors
EuropeanJournalofHeartFailureÂ©2014EuropeanSocietyofCardiology
4 M.BrÃ¤nnstrÃ¶mandK.Boman
withnurseswhousedamodelforperson-centredpalliativecare.
ThemodeliscalledthesixSsandconsistofthesixSkeywords;
self-image, self-determination, social relationships, symptom con-
trol,synthesis,andsurrender,12andcontinuedthrough;(iv)regular
meetings about the patientsâ€™ conditions within the team twice a
month;and,finally,(v)betweenthemeetingsbriefdiscussionstook
placeoutbetweentheteammembers(n=7)attheunitandinfor-
mationwassharedbythedocumentationinmedicalrecordsand
phonecalls.
The team was responsible for the total care, i.e. including
co-morbidities.Assessmentsofsymptoms,QoL,andrisksofdecu-
bitus, falling, and malnutrition were continually performed in a
structured way with validated questionnaires or in the national
qualityofcareregistrybytheSwedishAssociationofLocalAuthor-
ities and Regions (SALAR). Further registrations in the national
palliative registry and heart failure registry were performed. The
Swedish Palliative Registry is a nationwide quality registry aimed
atimprovingend-of-lifecare.Thegoaloftheregistryistolistand
report quality indicators related to care during the last week of
lifeinthecaseofallexpecteddeathsinSweden.Thiswasfulfilled
byeachprofessionanddocumentedindependently,butalsointhe
teaminordertosupportthepatientandattainthegoals.Thestruc-
ture of care was also based on goals and steps in the process of
providingpalliativecareforpatientswithCHFasrecommendedby
theESC1,5,9anddevelopedwithinthePREFERmodelasdescribed
previously.12
Oneoftheresearchers(M.B.)wasnotinvolvedinthetreatment
andcareofthepatients;theotherresearcher(K.B.)sharedrespon-
sibilityforcardiactreatmenttogetherwithageneralpractitioner
specializedinpalliativemedicine.
Assessments and outcomes
Prospective assessments were made at baseline and 1, 3, and 6
months of follow-up using the Edmonton Symptom Assessment
Scale(ESAS),EuroQol(EQ-5D),andKansasCityCardiomyopathy
Questionnaire(KCCQ).Socio-demographicandclinicalcharacter-
isticsweremeasuredatbaselineusingapre-specifiedprotocol.Ifa
categoricalvariablewasdenotedasunknownitwasregisteredas
anoanswer.Thequestionnaires(Qs)werefilledinbythepatients
themselves,baseline.Atandthefinal6monthQswerefilledinat
theresearchunit.Atthe1and3monthvisits,Qswerefilledinat
homeandreturnedinanenvelope.Theresponseratewas100%
atbaselineand1month.At2months,fourQsweremissingand
at6monthssixQsweremissing(oneduetodementia).
TheESAS,avalidandreliabletool,13wasusedtomeasuresymp-
tom burden: pain, tiredness, nausea, depression, anxiety, drowsi-
ness, appetite, well-being, and shortness of breath. The severity
ofeachsymptomatthetimeofassessmentisratedona10-item
numericalscale.13Theitemâ€˜otherâ€™wasnotincludedintheanalysis
duetoveryfewanswers.
TheHRQLwasmeasuredusingEQ-5D,ageneric,singleindex
thatdefineshealthinthefivedimensionsofmobility,self-care,usual
activities, pain/discomfort, and anxiety/depression.14,15 For each
dimension, the health of the patient is rated by the patient on a
........................................................................................................................................................................ 5-pointscaleEQ-5D5L:20noproblem,slightproblems,moderate
problems, severe problems, and impossible or extremely difficult
problems.AVASwasalsoused.14
The QoL was also measured using the disease-specific instru-
ment, the KCCQ, which measures physical limitation, symptoms
(frequency, severity, and recent change over time), QoL, social
interference, and self-efficacy. The KCCQ is a valid and reliable
instrumentinaSwedishCHFpopulation.16Scoresaretransformed
toarangeof0â€“100,inwhichhigherscoresreflectbetterhealth
status.
Statistical analysis
Patients with CHF (NYHA class IIIâ€“IV) were considered to have
a mean total symptom burden corresponding to 50 points out
of 100 according to the ESAS scale and compared with findings
by Follwell etal.17 for patients with cancer. The patients in that
studyhad ameanESASDistressScore(EDS)of39.5atbaseline,
and a mean improvement in the EDS of 8.8 points. The PREFER
model was created to improve the mean symptom burden by at
least25%comparedwiththecontrolgroup.Withapowerof80%,
significance level of P<0.05, and an estimated drop-out rate of
15%,31patientswereneededineacharm(total62patients).Due
to patients dropping out, mainly due to deaths (12 patients), the
numberofparticipantswasincreasedto36ineacharm.
Results are presented as the meanÂ±standard deviation (SD)
or frequencies expressed as percentages. Comparisons between
the intervention and control groups were made using the ðœ’2
test for proportions and Studentâ€™s t-test for normally distributed
continuousvariables.TheShapiroâ€“Wilkstatisticwasusedtotest
normality. If the distributions were not normal or ordinal, the
Mannâ€“WhitneyU-testorðœ’2withFisherâ€™sexacttestforcategorical
variables was used. For within-group analysis of non-normally
distributeddata,theWilcoxonmatched-pairsigned-ranktestwas
used. Logistic regression analysis was used to calculate the odds
ratio and 95% confidence interval for different variables after
adjusting for age differences between the groups. All analyses
were performed on an intention-to-treat basis. A P-value <0.05
was considered significant. The data were analysed using PASW
Statistics18.
Ethics
Oral and written informed consent was obtained from all
participants. The investigation conforms to the principles out-
lined in the Declaration of Helsinki, 1964. The Regional Ethics
Committee for Human Research at UmeÃ¥ University (reference
number2010-294-31M)approvedthestudy,whichwasregistered
atwww.clinicaltrials.gov(registrationnumberNCT01304381).
Results
FromJanuary2011toOctober2012,werandomized72patients
(36 in the PREFER and 36 as controls, i.e. usual care). The
Â©2014TheAuthors
EuropeanJournalofHeartFailureÂ©2014EuropeanSocietyofCardiology
PREFER:arandomizedcontrolledstudy 5
two groups were balanced with respect to baseline character-
istics except for mean age (PREFER 81.9Â±7.2years vs. control
76.6Â±10.2years,P=0.012;Table1).
All patients were regarded as optimally treated by their physi-
cians, and pharmacological treatment was characterized by a
relatively high number of evidence-based therapies with regard
to inhibitors of the reninâ€“angiotensin system, beta-blockers, and
mineralocorticoid receptor antagonists (Table 1). There were a
number of serious co-morbidities but there was no statistically
significant difference between the two groups (Table 1). Twelve
patientsdiedduringthestudy;theremaining60patientscompleted
thestudy.
Euro Qol-5D: health-related quality of life
No difference was found between the two treatment groups
at baseline for HRQL assessed with the EQ-5D. At 6 months,
the PREFER group had an increased HRQL, from 47.7Â±19.4 to
60.4Â±20.6,comparedwith48.2Â±23.1vs.52.3Â±23.2forcontrols
(age-adjusted P-value=0.10). The between-group analysis of the
age-adjusteddelta-valueofHRQLfrombaselineto6monthswas
significantly(P=0.02)betterforpatientsinthePREFERgroupthan
forcontrols.
If the last measurement at 1, 3, or 6 months was analysed,
the delta-difference of HRQL, after adjusting for age, was still
significantlybetter(P=0.04)inthePREFERgroup.
ForthefivedimensionsoftheEQ-5D(mobility,self-care,usual
activities, pain/discomfort, and anxiety/depression), no significant
differenceswerefoundbetweenthegroups(datanotshown).
In a paired within-group analysis of the PREFER group, HRQL
increased 28% from baseline to 6 months (from 46.9Â±21.3 to
60.4Â±20.6,P=0.013).IfallmeasurementsofHRQL(1,3,and6
months)wereincluded,theincreasewas20%(from48.2Â±19.8to
57.6Â±19.2,P=0.026).Correspondingvaluesforthecontrolgroup
were3%(from50.7Â±24.2to52.3Â±23.2,P=0.61)and1.0%(from
48.7Â±24.0 to 49.6Â±23.8, P=0.74), respectively. For the other
dimensions,nosignificantdifferenceswerefound.
The Edmonton Symptom Assessment
Scale
No significant differences were found between the PREFER and
control groups in regard to any item of the ESAS scale or after
adjusting for age difference (data not shown). Nausea was signif-
icantly improved (2.3Â±2.7 vs. 1.2Â±1.7, P=0.02) in the PREFER
group,butnotinthecontrolgroup.Numericalimprovementswere
observedineightoutofnineitemsinthePREFERgroupcompared
with four out of nine in the control group. The item â€˜otherâ€™ was
notincludedduetoveryfewanswers,
Kansas City Cardiomyopathy
Questionnaire
Nosignificantdifferenceswerefoundbetweenthetwotreatment
groups for all dimensions of the KCCQ at baseline (data not
........................................................................................................................................................................ shown)and6months.However, inthePREFERgroup,wenoted
an increase in 19 summary scores and a decrease in one. The
increasewasstatisticallysignificantfortotalsymptomburden(18%,
P=0.035),self-efficacy(17%,P=0.041),andQoL(24%,P=0.047;
Table2).
In the control group, we found no significant difference in
any dimension (data not shown). Increases were observed in 11
dimensionsanddecreasesin9.
Functional classes
FunctionalclassesimprovedinthePREFERgroupcomparedwith
controls,includingasignificantdifferenceinmeanNYHAclassat
6months(2.9Â±0.65vs.3.3Â±0.58,P=0.012,baseline3.2vs.3.1;
Table 3). In the PREFER group, improvement was seen in 11 out
of28(39%)vs.3outof32(9%)inthecontrolgroup(P=0.015).
WorseningNYHAfunctionalclasswasfoundin2outof28(7%)
vs.5outof32(16%)patientsinthePREFERandcontrolgroups,
respectively.
Hospitalizations
The mean number of hospitalizations was significantly lower in
the PREFER group than in the control group (0.42Â±0.60 vs.
1.47Â±1.81, P=0.009; Table 4). The total number of hospitaliza-
tionswas15inthePREFERgroupand53inthecontrolgroup.The
totalnumberofdaysspentinhospitalwas408,range1â€“46days,
being103(range1â€“45days)inthePREFERgroupand305(range
2â€“46 days) in the control group. The mean number of days was
significantly(2.9Â±8.3vs.8.5Â±12.4,P=0.011)lowerinthePRE-
FERgroupcomparedwiththecontrolgroup.Thenumberofdays
spentinhospitalwasalsosignificantlylowerinthePREFERgroup
at the Departments of Medicine-Geriatrics (100, range 1â€“45 vs.
242, range 2â€“46 days) and Surgery (0 vs. 56, range 2â€“21 days)
(Table3).Daysinotherdepartmentsdidnotdiffersignificantly(3,
range1â€“2vs.7,range1â€“6days).
Nostatisticallysignificant(P=0.34)difference(8vs.4patients)
inmortalityoccurredduring6months.
Resource utilization
There were significant differences in the utilization of visits and
phone calls or prescriptions of physicians and nurses between
the PREFER and usual care group at the outpatient clinic of the
hospitalsandtheprimaryhealthcarecentres(Table4).Additionally,
withinthePREFERteamtherewere158additionalphysicianvisits
and 1031 nurse visits at the patientâ€™s home, and 36 phone call
and/or drug prescriptions by the physician and 225 phone calls
and/orprescriptionsbythenurses.Summarizingallthis,themost
strikingdifferencewasfoundbetweennursevisitsinthePREFER
groupandtheusualcaregroup(1075vs.230;P=0.000).Onthe
otherhand,phonecallsandprescriptionsbydoctorsweremore
common in the usual care group (108 vs. 231), while physicianâ€™s
visitsweresomewhatsimilar(194vs.201).
Â©2014TheAuthors
EuropeanJournalofHeartFailureÂ©2014EuropeanSocietyofCardiology
6 M.BrÃ¤nnstrÃ¶mandK.Boman
Table1 Baselinecharacteristics
PREFER, Usualcare, P-value
n=36 n=36
...........................................................................................................................................
Female 10(27.8) 11(30.6) 0.80
Age,years 81.9Â±7.2 76.6Â±10.2 0.012
Civilstatus
Single 14(39) 14(39) 1.00
Married/co-habiting 22(61) 22(61) 1.00
Smoking
Never 13(36.1) 14(38.9) 0.81
Former 21(58.3) 17(47.2) 0.35
Actual/unknown 2(5.6) 5(13.8) 0.23
Alcohol
Never 15(41.7) 13(36.1) 0.09
Regularuse 16(44.4) 17(47.2) 0.41
Unknown 5(13.9) 6(16.7) 0.26
HistoryofprimaryCVDforCHF 26(77.2) 26(77.2) 1.00
Ischaemicheartdisease 13(36.1) 13(36.1) 1.00
Arterialhypertension 9(25.0) 9(25.0) 1.00
Valvedisease 1(2.8) 1(2.8) 1.00
Dilatedcardiomyopathy 1(5.6) 0(0.0) 0.10
Other 2(5.6) 3(8.4) 0.64
Unknown 10(28.0) 10(28.0) 1.00
Historyofatrialfibrillationorflutter 23(63.9) 22(61.1) 0.81
Historyofpulmonarydisorder 15(41.7) 18(50) 0.48
Historyofstroke 14(38.9) 12(33.3) 0.56
Historyofdiabetes 13(19.4) 8(16.6) 0.07
Historyofdepression 6(16.7) 12(33.3) 0.30
Historyofrenaldisorder 10(27.8) 11(30.6) 0.57
Historyofmalignancy 6(16.7) 2(5.6) 0.13
Creatinine>130mmol/L 12(33.3) 12(33.3) 1.00
GFR<60mL/min 25(69.4) 22(61.1) 0.46
Anaemia<120 19(52.7) 15(41.7) 0.29
NYHAIII 28(77.8) 23(63.9) 0.34
NYHAIV 8(22.2) 11(30.6) 0.34
Dyspnoea
None 1(2.8) 2(5.6) 0.56
Mild 8(22.2) 6(16.6) 0.55
Moderate 23(63.9) 22(61.1) 0.81
Severe 4(11.1) 6(16.7) 0.50
Fatigue
None/missing 3(8.3) 4(11.1) 0.69
Mild 10(27.8) 7(19.4) 0.41
Moderate 16(44.4) 15(41.7) 0.81
Severe 7(19.4) 10(27.8) 0.41
Bloodpresssure
Systolic,mmHg 124Â±25.8 120Â±19.9 0.42
Diastolic,mmHg 70Â±12.5 74Â±9.7 0.12
Systolicfunction
EF40â€“49 13(36.1) 12(33.3) 0.80
EF30â€“39 16(44.4) 21(58.3) 0.36
EF<30 7(19.4) 3(8.3) 0.17
Treatment
RASblockade 32(86.1) 33(91.7) 0.69
Beta-blocker 30(83.3) 31(86.1) 0.74
MRA 10(27.8) 13(36.1) 0.45
Loopdiuretics 32(88.9) 30(83.3) 0.50
Digitalis 8(22.2) 5(13.9) 0.36
Â©2014TheAuthors
EuropeanJournalofHeartFailureÂ©2014EuropeanSocietyofCardiology
PREFER:arandomizedcontrolledstudy 7
Table1 Continued
PREFER, Usualcare, P-value
n=36 n=36
...........................................................................................................................................
Nitrates 12(33.3) 11(30.6) 0.80
Statins 12(33.3) 18(50.0) 0.15
Anticoagulants 17(47.2) 17(47.2) 1.00
ASA/Trc.inh. 21(58.3) 15(41.7) 0.16
No.ofotherdrugtreatments,median 5 6 0.73
Devices,procedures
CRTwithoutICD 2(5.6) 2(5.6) 1.00
Pacemaker 4(11.1) 5(13.9) 0.72
Valveoperations 4(11.1) 3(8.3) 0.69
HistoryofCABG/PCI 17(47.2) 13(36.1) 0.34
Dataaregivenasn(%)ormeanÂ±standarddeviation.
ASA,acetylsalicylicacid;CABG,coronaryarterybypassgraft;CHF,chronicheartfailure;CVD,cardiovasculardisease;GFR,glomerularfiltrationrate;ICD,implantable
cardioverterdefibrillator;MRA,mineralocorticoidreceptorantagonist;RAS,reninâ€“angiotensinsystem;Trc.Inh.,thrombocyticinhibitor.
Table2 Thewithin-groupanalysisofalldimensionsofKansasCityCardiomyopathyQuestionnaireinthe
PREFER-treatedpatients
KCCQ-12 n MeanÂ±SD n MeanÂ±SD P-value
...........................................................................................................................................
Physicallimitation,bl.â€“6m 24 58.5Â±21.9 60.0Â±26.2 0.93
Physicallimitation,bl.,1â€“6m 33 55.1Â±24.1 55.3Â±27.3 0.83
Symptomstability,bl.â€“6 26 51.0Â±25.0 55.8Â±24.8 0.60
Symptomstability,bl.,1â€“6m 34 51.4Â±22.1 52.2Â±23.3 0.97
Symptomfrequency,bl.â€“6m 25 59.1Â±22.5 65.8Â±27.6 0.13
Symptomfrequency,bl.,1â€“6 33 56.4Â±21.4 58.2Â±29.6 0.63
Symptomburden,bl.â€“6 27 58.8Â±21.4 63.3Â±28.5 0.15
Symptomburden,bl.,1â€“6m 35 59.2Â±20.2 59.6Â±26.5 0.67
Totalsymptomscore,bl.â€“6m 26 55.9Â±20.6 65.8Â±25.8 0.041
Totalsymptomscore,bl.,1â€“6m 34 56.7Â±20.2 59.3Â±27.3 0.37
Self-efficacyscore,bl.â€“6m 26 50.5Â±29.0 59.1Â±25.1 0.24
Self-efficacyscore,bl.,1â€“6m 33 48.9Â±28.2 61.7Â±26.9 0.041
QoL,bl.â€“6m 27 49.5Â±24.7 61.3Â±26.6 0.047
QoL,bl.,1â€“6m 34 51.8Â±24.7 58.8Â±24.9 0.21
Sociallimitation,bl.â€“6m 22 53.9Â±24.6 59.9Â±28.1 0.35
Sociallimitation,bl.,1â€“6m 29 56.1Â±23.1 57.5Â±27.9 0.76
Overallsummaryscore,bl.â€“6m 33 53.3Â±18.9 51.4Â±34.3 0.96
Overallsummaryscore,bl.,1â€“6m 31 56.7Â±16.7 59.5Â±21.9 0.22
Clinicalsummaryscore,bl.â€“6m 30 54.0Â±20.7 55.7Â±30.1 0.47
Clinicalsummaryscore,bl.,1â€“6m 33 55.5Â±18.3 57.7Â±24.9 0.34
ThecomparisonovertimewithinthePREFERarm.
bl.â€“6mdenoteschangesfromthebaselinevaluetothevalueat6monthsandbl.,1â€“6mdenotesvaluesalsoat1and3monthsinthecaseofmissingvaluesat6months.
Scoresaretransformedtoarangeof0â€“100,inwhichhigherscoresreflectbetterhealthstatus.
KCCQ,KansasCityCardiomyopathyQuestionnaire;QoL,qualityoflife.
Discussion
OurmainfindingsweresignificantimprovementswiththePREFER
interventioncomparedwithusualcareinregardstoHRQL,NYHA,
and morbidity, with reductions in the number of hospitalizations
anddaysspentinhospital.Moreover,inthewithin-groupanalysis
oftheusualcareandthePREFERgroups,patientsinthePREFER
group showed increases in most dimensions of the KCCQ, and
........................ were significantly improved in terms of total symptom burden,
self-efficacy,andQoL.Thesymptomaticimprovementofpatients
inthePREFERgroupwasaccompaniedbyamarkedreductionin
theneedforhospitalization.
The PREFER model was developed from the goals and steps
in the process of providing palliative care for patients with CHF
as recommended by the ESC.1,5,9 These were: patient features;
confirmdiagnosis;patienteducation;establishmentofanadvanced
Â©2014TheAuthors
EuropeanJournalofHeartFailureÂ©2014EuropeanSocietyofCardiology
8 M.BrÃ¤nnstrÃ¶mandK.Boman
Table3 Distributions,meanvalues,andchangesoffunctionalclassesattheendofstudy,andtotalnumberandmean
numberofhospitalizationsperpatientduringthestudy
PREFER MeanÂ±SD Control MeanÂ±SD P-value
n N
...........................................................................................................................................
NYHA
NYHAI 1 0
NYHAII 5 2
NYHAIII 19 19
NYHAIV 3 11
NYHA 2.9Â±0.65 3.3Â±0.58 0.012
NYHAchange 0.037
Improved 11 3
Unchanged 15 24
Worse 2 5
Morbidity
Hospitalizations,n,meanÂ±SD 15 0.42Â±0.60 53 1.47Â±1.81 0.009
Numbers,total 15 53
None 23 15
1 11 9
2 2 2
3 0 5
4 0 2
5 0 2
7 0 1
care plan; required organization of services; symptom manage-
ment;identifyingend-stageheartfailure;breakingbadnewstothe
patientandfamily;andestablishingnewgoalsforcare.ThePREFER
modelalsoincludesgoalsofsupporttorelatives/bereavementand
totheteammembers.12 ThestrategyusedinthePREFERmodel
goes beyond traditional heart failure management at hospitals by
includingperson-centredandspecializedpalliativecare.
Oneofthemaindifferencesfromstandardheartfailuremanage-
mentisthatthePREFERteamtakesmorecomprehensivecareof
theperson,takingintoconsiderationsymptomsandsignsrelated
toaccompanyingco-morbidities,suchasstroke,renaldysfunction,
pulmonarydisorders,anaemia,andevencancer,whichwerecom-
moninthepresentstudy.
InthePREFERgroup,weusedPCCinadditiontotheidentity-
promoting care concept applied to palliative care planning.12
Earlierstudiesshowedthatbeingmetasaperson(i.e.withtrust
andawillingnesstohelp)byprofessionalcaregiversathomeseems
to increase feelings of security,18 and that seeing the patients in
theirhomesituationhelpstheteamtotailorcaretothepersonsâ€™
wayoflife.19 Tothebestofourknowledge,thisisthefirststudy
to evaluate a new approach for CHF management by integrating
specializedpalliativehomecareandheartfailurecare.Thisstudy
provides new information about the PREFER model resulting in
improved HRQL, total symptom burden, and NYHA functional
class in association with reductions in the number of hospitaliza-
tions and days spent in hospital at both the Medicine-Geriatrics
and Surgery departments. These findings are in line with the
results of the PCC-HF study,20 which showed that PCC during
in-hospital care impacts the length of stay in the hospital and
maintainedfunctionalperformance.
......................................................................................... Relapses and rehospitalizations are very common in patients
withCHF.Thisconditionhasthehighestrateofrehospitalization
at departments of medicine21 and is very costly and resource
demanding.22 County councils expend much effort, with limited
success,toreduceboththelengthofstayandrehospitalizationfor
thesepatients.InlinewithKossovskyetal.,23Clarke,24andEkman
etal.,20wealsosupporttheideathatrelapsesandlengthofstayand
rehospitalizationcanbereducedbyimprovingthequalityofcare,
and that common practice should be rethought and re-evaluated
withregardtoshorteningofthelengthofhospitalizationsthrough
rapiddischargeaftersymptomrelief.Anothertypeofstructureof
CHFcarealsoseemstobeneeded.9 Themanagementofpatients
withCHFandtheirco-morbiditiesisverycomplexandachallenge
toallofthehealthcarepersonnelandsystemsinvolved.WhileCHF
is largely managed in primary care in mild to moderate stages,
the problems arise in more advanced situations, especially when
the syndrome of CHF is accompanied by co-morbidities. This is
not easily handled by primary healthcare physicians.25 A bridge
between acute care of CHF at hospitals and primary healthcare
hasbeensuccessfullyfulfilledbyheartfailureclinics,26whichfocus
primarily on the management of heart failure. The strategy of
PREFERgoesbeyondtraditionalheartfailuremanagementinclinics
by including specialized palliative care as practised for cancer
patients. One of the main differences from standard heart failure
managementisthatPREFERalsotakesmorecomprehensivecare
of accompanying co-morbidities. The team is responsible for the
totalcareofthepatient.Assessmentofsymptoms,QoL,andrisks
of decubitus, falling, and malnutrition is continual. This does not
mean that responsibility is removed from the patientâ€™s general
practitionerorotherspecialists,butratherthattheyareincluded
Â©2014TheAuthors
EuropeanJournalofHeartFailureÂ©2014EuropeanSocietyofCardiology
PREFER:arandomizedcontrolledstudy 9
Table4 Totalnumberofphysicianandnursevisits,
phonecalls,and/ordrugprescriptionsatthe
outpatientclinicsofthehospitalsandattheprimary
healthcarecentres.
PREFER Usualcare P-value
n n
................................................................
Hospitaloutpatientclinic
Physicianvisits,n 27 133 0.000
Median(minâ€“max) 1(4â€“30) 3(2â€“11)
Physician,phs.,pres.,n 42 86 0.012
Median(minâ€“max) 3(0â€“8) 3(0â€“10)
Nursevisits,n 4 60 0.003
Median(minâ€“max) 1(0â€“4) 2(0â€“27)
Nurse,phs.,pres.,n 8 44 0.003
Median(minâ€“max) 1(0â€“4) 2(0â€“8)
PHC
Physicianvisits,PHC,n 9 54 0.027
Median(minâ€“max) 1(0â€“3) 2(0â€“8)
Physician,phs.,pres.,n 30 145 0.000
Median(minâ€“max) 1(0â€“5) 1(1â€“14)
Nursevisits,PHC,n 29 61 0.25
Median(minâ€“max) 1(0â€“12) 2(0â€“14)
Nurse,phs.,pres.,n 59 153 0.010
Median(minâ€“max) 3(0â€“9) 4(1â€“21)
Physicianvisits,home,n 0 14
Median(minâ€“max) 0(0â€“0) 2,(1â€“5)
Nursevisits,home,n 11 109 0.032
Median(minâ€“max) 2(1â€“3) 5(1â€“23)
PHC,primaryhealthcarecentre;Phs,phonecalls;pres,prescriptions.
inthecollaboration.PREFERisalsoorganizedincloseco-operation
with out-of-hours palliative advanced home care. This team is
fullyinformedoftheidentitiesofthepatientsandknowshowto
respondtocalls.
On the other hand, PREFER differs from traditional palliative
care by including active heart failure treatment with acute heart
resuscitation if needed, according to the patientâ€™s expressed
desire.19,27Evenmoreimportantistheintentiontouseallmodern
pharmacological treatments and other types of devices, such as
CRT, if necessary, to reduce symptom burden. The decision to
include this form of active treatment arises from the difficulty
in defining a transition point to palliative care for heart failure
patients.19,27,28 Theirlivesaresometimesdescribedasâ€˜livingnear
deathâ€™orâ€˜arollercoasterlifeâ€™,i.e.anongoingoscillationbetween
ups and downs.18 The unpredictable progression of the illness
leads to a great risk that these patients and their close relatives
willnothaveaccesstopalliativecare.1,5
The mechanisms underlying the favourable results are not evi-
dent.Severalcomponentsareprobablyrelatedtoeachother,and
it could be difficult to separate them to explain the effectiveness
oftheintervention.29 Insomecases,therecognitionofimportant
co-morbiditiesismoreimportantthanthesyndromeofCHFper
se. In other cases, undertreatment of the CHF condition may be
anexplanation.Despitetheparticipatingpatientsbeingregardedas
........................................................................................................................................................................ â€˜optimallytreatedâ€™bytheirphysicianbeforeinclusioninthestudy,a
numberofpatientshadtheirmedicationsre-evaluated,up-titrated,
andrigorouslycheckedaccordingtooptimalevidence-basedther-
apyforCHF.Nevertheless,theimpactofphysiological,psychoso-
cial, and spiritual problems should be recognized. The continuity
oftheteam,accessibility,andthepossibilityofvisitsandexamina-
tionsatpatientsâ€™homesareimportantmeasuresforlesseningthe
patientâ€™s total symptom burden. The confidence, availability, and
trust in the PREFER team may have had a substantial impact on
patientsâ€™HRQLandneedforhospitalcare.Also,theinvolvementof
awifeorhusbandandotherrelativesmaybeimportant.30Anum-
ber of explanations are possible as the PREFER concept involves
differentstrategiesinvolvingspecialistcompetencesfromdifferent
areas:generalpractitionersanddoctorstrainedinpalliativecare,
cardiologists,nurses,physiotherapists,andoccupationaltherapists.
We consider that the PCC has had a substantial impact on the
results. One of the main differences between the two strategies
wasthenursevisitsatthepatientâ€™shome,whichweresubstantially
and significantly more frequent in the PREFER group compared
withtheusualcaregroup.Thismadeitpossibletocarryoutthe
structured,PCCathome.Moreover,besidestheupdatingofdrug
treatmentaccordingtorecentguidelinesbothfordrugtreatment
anddevicetherapy,wehypothesizethatthecontinuityofthesame
personnel,beingarathersmallgroup,wasofimportance.Thepos-
sibilityforthepatientstoreachthepersonneleasilybyphoneand
thattreatmentoftencouldtakeplaceatthepatientâ€™shomeinstead
of them being admitted to hospital may have contributed to the
achievedresults.ThesestepsofthePREFERconceptmayhavecre-
atedconfidenceinandreassurancebythecaregivenandreduced
patientsâ€™anxiety.
Further research is needed to evaluate the separate impact
of each component of the PREFER concept, if possible, and its
contributiontothebeneficialeffectsfoundinthepresentstudy.
Limitations
Our findings have a number of limitations. First, patients in the
PREFER group were significantly older than those in the control
group,butthisdifferencewasadjustedforinthefollow-upanalyses.
Secondly,theoutcomeanalyseswerenotblinded;functionalclass
was evaluated by physicians involved in the trial. Questionnaires
were filled out by participating patients who knew the group to
which they belonged. This may have introduced some bias into
thesymptomreportingandassessmentofNYHAclasses.Thirdly,
this study was small and at a single centre, which should be
considered when interpreting and generalizing the study findings.
Although the number of patients was limited, a strength of this
studywasthatweincludedpatientswithahighnumberofsevere
co-morbidities that are seldom accepted in most randomized
clinical trials. The exclusion criteria were mostly for practical or
administrativereasons,soweconsiderthepatientsinthisstudyto
berepresentativeofmanyelderlypatientswithmoderatetosevere
CHFtreatedinhospitalsandprimaryhealthcare.
Â©2014TheAuthors
EuropeanJournalofHeartFailureÂ©2014EuropeanSocietyofCardiology
10 M.BrÃ¤nnstrÃ¶mandK.Boman
Conclusion
Patient-centredcareseemedtorelievethephysical,physiological,
social, and spiritual problems of patients with severe CHF by
improvingHRQL,functionalclass,andtotalsymptomburden,and
reducedhospitalizationsandthenumberofdaysspentinhospital.
Ourfindingsalsochallengethetraditionalwayofcaringforelderly
patientswithCHFandaccompanyingco-morbidities.
Acknowledgements
Wewouldliketothanktheparticipantsforsharingdataabouttheir
illnesswithus,andClaesLundgrenMD,SkellefteaHospital,Sweden
forvaluablesupportinidentifyingeligiblepatientsforthestudy.
Funding
ThisworkwassupportedbytheSwedishAssociationofLocalAuthor-
ities and Regions, the Swedish Heart and Lung Association, and the
RonnbaretFoundationSkellefteaMunicipality.
Conflictofinterest:nonedeclared.
References
1. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P,
Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW,
Keren A, Mebazaa A, Nieminen M, Prior SG, Swedberg K. ESC Committee
forPracticeGuidelines(CPG).ESCGuidelinesforthediagnosisandtreatment
ofacuteandchronicheartfailure2008:theTaskForcefortheDiagnosisand
TreatmentofAcuteandChronicHeartFailure2008oftheEuropeanSocietyof
Cardiology.DevelopedincollaborationwiththeHeartFailureAssociationofthe
ESC(HFA)andendorsedbytheEuropeanSocietyofIntensiveCareMedicine
(ESICM).EurHeartJ2008;29:2388â€“2442.
2. BeernaertK,CohenJ,DeliensL,DevroeyD,VanthommeK,PardonK,Van
denBlockL.ReferraltopalliativecareinCOPDandotherchronicdiseases:
apopulation-basedstudy.RespMed2013;107:1731â€“1739.
3. McDonaghTA,BlueL,ClarkAL,DahlstromU,EkmanI,LainscakM,McDonaldK,
RyderM,StrombergA,JaarsmaT.EuropeanSocietyofCardiologyHeartFailure
AssociationCommitteeonPatientCare.EuropeanSocietyofCardiologyHeart
FailureAssociationStandardsfordeliveringheartfailurecare.EurJHeartFail
2011;13:235â€“241.
4. BrannstromM,HagglundL,FurstCJ,BomanK.Unequalcarefordyingpatients
inSweden:acomparativeregistrystudyofdeathsfromheartdiseaseandcancer.
EurJCardiovascNurs2012;11:454â€“459.
5. JaarsmaT,BeattieJM,RyderM,RuttenFH,McDonaghT,MohacsiP,MurraySA,
GrodzickiT,BerghI,MetraM,EkmanI,AngermannC,LeventhalM,PitsisA,
AnkerSD,GavazziA,PonikowskiP,DicksteinK,DelacretazE,BlueL,StrasserF,
McMurrayJ.AdvancedHeartFailureStudyGroupoftheHFAoftheESCPalliative
careinheartfailure:apositionstatementfromthepalliativecareworkshopof
theHeartFailureAssociationoftheEuropeanSocietyofCardiology.EurJHeart
Fail2009;11:433â€“443.
6. World Health Organization. National Cancer Control Programmes. Policies and
managerialguidelines.2nded.Geneva,2002.
7. Evangelista LS, Lombardo D, Malik S, Ballard-Hernandez J, Motie M, Liao S.
Examiningtheeffectsofanoutpatientpalliativecareconsultationonsymptom
burden,depression,andqualityoflifeinpatientswithsymptomaticheartfailure.
JCardFail2012;18:894â€“899.
................................................................................................................................................... 8. GomesB,CalanzaniN,CurialeV,McCroneP,HigginsonIJ.Effectivenessand
cost-effectivenessofhomepalliativecareservicesforadultswithadvancedillness
andtheircaregivers.CochraneDatabaseSystRev2013;6:CD007760.
9. BrannstromM,BomanK.Anewmodelforintegratedheartfailureandpalliative
advancedhomecareâ€”rationaleanddesignofaprospectiverandomizedstudy.
EurJCardiovascNurs2013;12:269â€“275.
10. JonssonA,EdnerM,AlehagenU,DahlstromU.Heartfailureregistry:avaluable
toolforimprovingthemanagementofpatientswithheartfailure.EurJHeartFail
2010;12:25â€“31.
11. Ekman I, Swedberg K, Taft C, Lindseth A, Norberg A, Brink E, Carlsson J,
Dahlin-IvanoffS,JohanssonIL,KjellgrenK,LidenE,OhlenJ,OlssonLE,RosenH,
RydmarkM,SunnerhagenKS.Person-centeredcareâ€”readyforprimetime.Eur
JCardiovascNurs2011;10:248â€“251.
12. TernestedtB.Adignifieddeathandidentity-promotingcare.In:NordenfeltL,ed.
DignityinCareforOlderPeople.Oxford:Wiley-Blackwell;2010.p146â€“165.
13. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom
AssessmentScale.Cancer2000;88:2164â€“2171.
14. EuroQol G. EuroQolâ€”a new facility for the measurement of health-related
qualityoflife.HealthPolicy1990;16:199â€“208.
15. Ellis JJ, Eagle KA, Kline-Rogers EM, Erickson SR. Validation of the EQ-5D
in patients with a history of acute coronary syndrome. Curr Med Res Opin
2005;21:1209â€“1216.
16. PatelH,EkmanI,SpertusJA,WassermanSM,PerssonLO.Psychometricprop-
ertiesofaSwedishversionoftheKansasCityCardiomyopathyQuestionnairein
achronicheartfailurepopulation.EurJCardiovascNurs2008;7:214â€“221.
17. FollwellM,BurmanD,LeLW,WakimotoK,SeccarecciaD,BrysonJ,RodinG,
ZimmermannC.PhaseIIstudyofanoutpatientpalliativecareinterventionin
patientswithmetastaticcancer.JClinOncol2009;27:206â€“213.
18. BrannstromM,EkmanI,NorbergA,BomanK,StrandbergG.Livingwithsevere
chronic heart failure in palliative advanced home care. Eur J Cardiovasc Nurs
2006;5:295â€“302.
19. BrannstromM,BrulinC,NorbergA,BomanK,StrandbergG.Beingapalliative
nurseforpersonswithseverecongestiveheartfailureinadvancedhomecare.Eur
JCardiovascNurs2005;4:314â€“323.
20. Ekman I, Wolf A, Olsson LE, Taft C, Dudas K, Schaufelberger M, Rodin G,
ZimmermannC.Effectsofperson-centredcareinpatientswithchronicheart
failure:thePCC-HFstudy.EurHeartJ2012;33:1112â€“1119.
21. GillumBS,GravesEJ,JeanL.TrendsinHospitalUtilization:UnitedStates,1988â€“92.
Vital and Health Statistics, Series 13, No. 124. US Department of Health and
HumanServices;1996.
22. Ryden-BergstenT,AnderssonF.ThehealthcarecostsofheartfailureinSweden.
JInternMed1999;246:275â€“284.
23. KossovskyMP,SarasinFP,ChopardP,Louis-SimonetM,SigaudP,PernegerTV,
GaspozJM.Relationshipbetweenhospitallengthofstayandqualityofcarein
patientswithcongestiveheartfailure.QualSafHealthCare2002;11:219â€“223.
24. ClarkeA.Lengthofin-hospitalstayanditsrelationshiptoqualityofcare.Qual
SafHealthCare2002;11:209â€“210.
25. SmithSM,SoubhiH,FortinM,HudonC,Oâ€™DowdT.Managingpatientswithmul-
timorbidity:systematicreviewofinterventionsinprimarycareandcommunity
settings.BMJ2012;345:e5205.
26. StrombergA,MartenssonJ,FridlundB,LevinLA,KarlssonJE,DahlstromU.
Nurse-ledheartfailureclinicsimprovesurvivalandself-carebehaviourinpatients
with heart failure: results from a prospective, randomised trial. Eur Heart J
2003;24:1014â€“1023.
27. BrannstromM,ForssellA,PetterssonB.Physiciansâ€™experiencesofpalliativecare
forheartfailurepatients.EurJCardiovascNurs2011;10:64â€“69.
28. HanrattyB,HibbertD,MairF,MayC,WardC,CapewellS,LitvaA,CorcoranG.
Doctorsâ€™perceptionsofpalliativecareforheartfailure:focusgroupstudy.BMJ
2002;325:581â€“585.
29. EkmanI,SwedbergK.Home-basedmanagementofpatientswithchronicheart
failureâ€”focusoncontentnotjustform!EurHeartJ2002;23:1323â€“1325.
30. Buck HG, Harkness K, Wion R, Carroll SL, Cosman T, Kaasalainen S, Kry-
woruchkoJ,McGillionM,Oâ€™Keefe-McCarthyS,SherifaliD,StrachanPH,Arthur
HM.Caregiversâ€™contributionstoheartfailureself-care:asystematicreview.Eur
JCardiovascNurs2014;inpress.
Â©2014TheAuthors
EuropeanJournalofHeartFailureÂ©2014EuropeanSocietyofCardiology
